Chengda Pharmaceutical Co., Ltd
Online roadshow announcement of initial public offering and listing on GEM
Sponsor (lead underwriter): Everbright Securities Company Limited(601788)
The application of Chengda Pharmaceutical Co., Ltd. (hereinafter referred to as the “issuer”) for initial public offering and listing on the gem (hereinafter referred to as the “issuance”) has been examined and approved by the GEM Listing Committee of Shenzhen Stock Exchange, and has been approved for registration by the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) (zjxk [2021] No. 3857).
The issuance adopts directional placement to strategic investors (hereinafter referred to as “strategic placement”) Offline inquiry placement (hereinafter referred to as “offline issuance”) to qualified offline investors and online pricing issuance (hereinafter referred to as “online issuance”) to social public investors holding non restricted A-share shares and market value of non restricted depositary receipts in Shenzhen market.
The issuer and the recommendation institution (lead underwriter) will directly determine the issuance price through offline preliminary inquiry, and offline cumulative bidding inquiry will not be conducted.
The strategic placement of this issuance consists of the special asset management plan established by the issuer’s senior management and core employees participating in this strategic placement and the follow-up investment of relevant subsidiaries of the sponsor (if any). If the offering price exceeds the median and weighted average of offline investors’ quotations after excluding the highest quotation, as well as the securities investment fund, national social security fund, basic old-age insurance fund established through public offering after excluding the highest quotation For the enterprise annuity fund established in accordance with the measures for the administration of enterprise annuity fund and the insurance fund quotation median and weighted average in accordance with the measures for the administration of the use of insurance funds, whichever is lower, the relevant subsidiaries of the sponsor will participate in the strategic placement of this issuance in accordance with the relevant provisions.
It is proposed to issue 24174035 shares to the public, and the total share capital after issuance is 96696140 shares. The proportion of publicly issued shares in the total share capital of the company is 25.00%. The initial number of strategic placement shares issued in this offering was 3.626105 million shares, accounting for 15.00% of this offering. Among them, the issuer’s senior management and core employees participated in the special asset management plan established by the strategic placement, and the initial strategic placement was 2417403 shares, accounting for 10.00% of the issuance; The initial strategic placement of relevant subsidiaries of the sponsor is 1208702 shares (if any), accounting for 5.00% of the issuance. The difference between the final strategic placement quantity and the initial strategic placement quantity is transferred back to offline issuance.
Before the launch of the call back mechanism, the initial offline issuance was 143839300 shares, accounting for 70.00% of the issuance after deducting the initial strategic placement, and the initial online issuance was 6164000 shares, accounting for 30.00% of the issuance after deducting the initial strategic placement. The total quantity of final offline and online issuance is the total quantity of this issuance minus the final strategic placement quantity. The final online issuance quantity and the final offline issuance quantity will be determined according to the call back situation.
In order to facilitate investors to understand the relevant information of the issuer and the relevant arrangements of this offering, the issuer and the sponsor (lead underwriter) Everbright Securities Company Limited(601788) will hold an online roadshow on this offering.
1. Online roadshow time: 14:00-17:00 on Friday, January 7, 2022;
2. Roadshow website: China Securities Journal · China Securities Network（ http://www.cs.com..cn./roadshow ）
3. Participants: key members of the issuer’s management and relevant personnel of the sponsor (lead underwriter) Everbright Securities Company Limited(601788) .
The full text of the prospectus and relevant materials of this offering can be found on five websites designated by the CSRC (cninfo, www.cn. Info. Com.. CN; CSI, www.cs. Com.. CN; China Securities, www.cn. Stock. Com; securities times, www.stcn. Com; Securities Daily, www.zqrb. CN) Consult.
Please pay attention to it.
Issuer: sponsor (lead underwriter) of Chengda Pharmaceutical Co., Ltd.: Everbright Securities Company Limited(601788) January 6, 2022 (this page has no text and is the seal page of the online roadshow announcement of Chengda Pharmaceutical Co., Ltd. on initial public offering and listing on GEM)
Issuer: Chengda Pharmaceutical Co., Ltd. (this page has no text and is the seal page of the online roadshow announcement of Chengda Pharmaceutical Co., Ltd. on initial public offering and listing on the GEM)
Sponsor (lead underwriter): Everbright Securities Company Limited(601788) mm / DD / yy
